Literature DB >> 21886516

Characterizing medical care by disease phase in metastatic colorectal cancer.

Xue Song1, Zhongyun Zhao, Beth Barber, Christopher Gregory, David Schutt, Sue Gao.   

Abstract

PURPOSE: To characterize patterns of medical care by disease phase in patients with newly diagnosed metastatic colorectal cancer (mCRC).
METHODS: Patients with mCRC newly diagnosed between 2004 and 2008 were selected from a large US national commercially insured claims database and were observed from initial mCRC diagnosis to death, disenrollment, or end of study period (July 31, 2009), whichever occurred first. The observation period was divided into three distinct phases of disease: diagnostic, treatment, and death. Within each phase, patterns of medical care were examined by the mutually exclusive service categories of inpatient, emergency room (ER), outpatient office and facility, outpatient pharmacy, chemotherapy, and biologic therapy, as measured by estimation of aggregate and category costs per patient per month.
RESULTS: A total of 6,675 patients with newly diagnosed mCRC were analyzed. Mean age was 64.1 years; 55.5% were males. Mean costs per patient per month for diagnostic, treatment, and death phases were $16,895, $8,891, and $27,554, respectively. Inpatient care was the primary driver of medical care for both the diagnostic (41.7% of costs) and death (71.4% of costs) phases. The largest category of medical care for the treatment phase was outpatient care (45.0% of costs). Chemotherapy and biologic therapy accounted for 15.6% and 17.6% of costs in the treatment phase, respectively.
CONCLUSION: Substantial differences in patterns of medical care were found between mCRC disease phases. Inpatient care was the key driver of medical care in the diagnostic and death phases compared with outpatient care in the treatment phase.

Entities:  

Year:  2011        PMID: 21886516      PMCID: PMC3092457          DOI: 10.1200/JOP.2011.000304

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN: 1554-7477            Impact factor:   3.840


  17 in total

1.  Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.

Authors:  Jean-Yves Douillard; Salvatore Siena; James Cassidy; Josep Tabernero; Ronald Burkes; Mario Barugel; Yves Humblet; György Bodoky; David Cunningham; Jacek Jassem; Fernando Rivera; Ilona Kocákova; Paul Ruff; Maria Błasińska-Morawiec; Martin Šmakal; Jean-Luc Canon; Mark Rother; Kelly S Oliner; Michael Wolf; Jennifer Gansert
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

2.  Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer.

Authors:  L Clark Paramore; Simu K Thomas; Kevin B Knopf; Lael S Cragin; Kathy H Fraeman
Journal:  Clin Colorectal Cancer       Date:  2006-05       Impact factor: 4.481

3.  The Surgical Pathology of Rectal Cancer: President's Address.

Authors:  C E Dukes
Journal:  Proc R Soc Med       Date:  1944-02

4.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.

Authors:  J Y Douillard; D Cunningham; A D Roth; M Navarro; R D James; P Karasek; P Jandik; T Iveson; J Carmichael; M Alakl; G Gruia; L Awad; P Rougier
Journal:  Lancet       Date:  2000-03-25       Impact factor: 79.321

5.  Treatment patterns and metastasectomy among mCRC patients receiving chemotherapy and biologics.

Authors:  Xue Song; Zhongyun Zhao; Beth Barber; Christopher Gregory; Peter Feng Wang; Stacey R Long
Journal:  Curr Med Res Opin       Date:  2010-12-06       Impact factor: 2.580

6.  Using healthcare claims data for outcomes research and pharmacoeconomic analyses.

Authors:  H G Birnbaum; P Y Cremieux; P E Greenberg; J LeLorier; J A Ostrander; L Venditti
Journal:  Pharmacoeconomics       Date:  1999-07       Impact factor: 4.981

7.  Systemic Therapy for Metastatic Colorectal Cancer: Patterns of Chemotherapy and Biologic Therapy Use in US Medical Oncology Practice.

Authors:  Gregory P Hess; Peter Feng Wang; David Quach; Beth Barber; Zhongyun Zhao
Journal:  J Oncol Pract       Date:  2010-11       Impact factor: 3.840

8.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

Authors:  L B Saltz; J V Cox; C Blanke; L S Rosen; L Fehrenbacher; M J Moore; J A Maroun; S P Ackland; P K Locker; N Pirotta; G L Elfring; L L Miller
Journal:  N Engl J Med       Date:  2000-09-28       Impact factor: 91.245

9.  FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.

Authors:  Christophe Tournigand; Thierry André; Emmanuel Achille; Gérard Lledo; Michel Flesh; Dominique Mery-Mignard; Emmanuel Quinaux; Corinne Couteau; Marc Buyse; Gérard Ganem; Bruno Landi; Philippe Colin; Christophe Louvet; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2003-12-02       Impact factor: 44.544

Review 10.  Metastatic colorectal cancer.

Authors:  H L Kindler; K L Shulman
Journal:  Curr Treat Options Oncol       Date:  2001-12
View more
  3 in total

1.  Cost of Disease Progression in Patients with Metastatic Breast, Lung, and Colorectal Cancer.

Authors:  Carolina Reyes; Nicole M Engel-Nitz; Stacey DaCosta Byfield; Arliene Ravelo; Sarika Ogale; Tim Bancroft; Amy Anderson; May Chen; Matthew Matasar
Journal:  Oncologist       Date:  2019-02-22

2.  Risk of unplanned visits for colorectal cancer outpatients receiving chemotherapy: a case-crossover study.

Authors:  Luisa Foltran; Giuseppe Aprile; Federica Edith Pisa; Paola Ermacora; Nicoletta Pella; Emiliana Iaiza; Elena Poletto; Stefania Eufemia Lutrino; Micol Mazzer; Mariella Giovannoni; Giovanni Gerardo Cardellino; Fabio Puglisi; Gianpiero Fasola
Journal:  Support Care Cancer       Date:  2014-04-13       Impact factor: 3.603

3.  Cost-effectiveness of adding Endocuff® to standard colonoscopies for interval colorectal cancer screening.

Authors:  Tiffany M Yu; Alison Tradonsky; Jun Tang; Renée Jg Arnold
Journal:  Clinicoecon Outcomes Res       Date:  2019-07-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.